Podcasts about next generation sequencing

If bladder issues in menopause are keeping you from jumping for bone density or for jumping for joy. Or if laughing and sneezing or a need to consider hydration needs against access to a bathroom are real life and every day concerns you… we've got you today.  Bladder issues in menopause don't need to keep you from activities, and they may come with signs and symptoms that aren't the obvious urgency, burning or leakage. The information here about testing beyond traditional options just might make you want to re-listen and share this one.    My Guest: Dr Kelly McCann is a board certified internist and pediatrician specializing in functional, integrative and environmental medicine. She graduated Brown undergrad, Tulane Med School, fellowship in Integrative Medicine at the University of Arizona. Her medical practice, the Spring Center, is located in Southern California. She hosted virtual summits on MCAS and can be found on many podcasts, summits and @drkellymccann.   Questions We Answer in This Episode: [00:09:09] What is a bacterial biofilm and how does that relate to bladder issues in women? [00:08:21] How do you know if you have a biofilm colonization? [00:13:26] Can you explain the testing technology and how it differs from a urinalysis and urine culture? [00:25:09] Other than UTIs and bladder issues, what might be some other signs that bacterial biofilms might be an issue?  [00:26:55] Are there other things that we should understand about this? (often associated with hypercoagulability which can mean an increased risk for heart disease) [00:30:58] Are there other options before or instead of antibiotics? If you personally got results back suggesting you do have bacteria, would you go the route of herbs or antibiotics?  [00:35:00] Cost of the test? And is it covered?    Bacterial Biofilm as Bladder Issues in Menopause   What is a Bacterial Biofilm? Mucus-like structures where bacteria live, can be found in the mouth, nose, GI tract, vagina, etc. These bacterial “homes” protect microbes from detection in standard lab tests. That means you can have symptoms, but your test results still show “normal.”   What is Next Generation Sequencing? Gives a complete and accurate picture of what's causing  your symptoms, even when your urinalysis and cultures are ‘normal'. Procedure: Scans the DNA of everything present in your sample (e.g. urine). Matches it to a vast DNA library of known organisms. Identifies exactly which microbes are in your bladder, how many, and in what percentages. Recommends treatment options by checking the medical literature for which antibiotics are effective against each bacteria. MicroGenDX does this test.   Signs You Might Have Biofilm Colonization: Chronic bladder symptoms (urgency, frequency, burning) without a confirmed UTI Recurrent UTIs that don't resolve or keep returning “Normal” urine tests but ongoing discomfort Other unexplained inflammation-driven symptoms like fatigue, rashes, headaches, joint pain, and more.   Relation to Heart Disease: Bacteria can travel from brushing your teeth and can end up in your coronary arteries and bladder. Biofilms can trigger clot formation for individuals who are genetically predisposed to forming clots or fibrin mesh. Systemic inflammation risk for individuals with low-level bacterial colonization that their body   Connect with Kelly: Website - Dr. Kelly McCann Website - The Spring Center Facebook - Dr. Kelly McCann Instagram - @drkellymccann    Other Episodes You Might Like: Previous Episode - Solving Sleep Issues with CBD and Other Perimenopause Symptom Solutions Next Episode - What Stem Cell Therapy Taught Me About Recovery, Mindset, and Reinventing Downtime More Like This - True Core Confidence: Revolutionizing Pelvic Floor Fitness After 40   Resources: Short & Easy Exercise videos in this 5 Day Flip Challenge. Don't know where to start? Book your Discovery Call with Debra.  

Send us a textCan embryos labeled as “abnormal” still lead to healthy babies? Are fertility clinics discarding embryos that could result in a pregnancy?In this episode of Taco Bout Fertility Tuesday, Dr. Mark Amols breaks down the controversy surrounding Preimplantation Genetic Testing for Aneuploidy (PGT-A). You've seen the headlines — abnormal embryos resulting in live births — but was the test actually wrong, or was it the interpretation?Learn the truth behind PGT-A and mosaicism, the evolution of embryo testing methods (FISH, aCGH, SNP, and NGS), and what the latest data says about success rates when transferring embryos diagnosed as aneuploid.Whether you're trying to understand your PGT-A results, deciding whether to transfer a mosaic embryo, or just looking for clarity in a confusing area of IVF science, this episode is your guide.

The field of Microbiology continues to change. Organisms were primarily identified in the clinical laboratory by biochemical testing. Then MALDI-TOF came to the lab and was incorporated into the workflow. Now labs are bringing next-generation sequencing (NGS). What is NGS? How does it work? Have you heard of Nanopore technologies? In this episode Dr. Jose Alexander and Daniel Navas from Advent Health Orlando, join the podcast to talk about NGS. They brought it to their laboratory and discuss the whole process, including the validation, challenges, and more. This episode was originally published on February 9th, 2024 Guest: Dr. Jose Alexander Daniel Navas Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro

Send us a textMarty speaks with Dr. Henry Erlich, whose research career gave him a front seat to the development of DNA sequencing technology from its infancy in the 80's, to the development of forensic applications in the criminal justice system in the 90's and through to it's maturity in Next Generation Sequencing methods now used to study evolutionary biology and the deep history of human and hominid evolution. His book is called 'Genetic Reconstruction of the Past - DNA analysis in Forensics and Human Evolution ', and its unifying theme is how we can now use DNA sequencing technology to study historical events, from the recent past in the case of forensic investigation of crimes, to the ancient past in studies of fossil remains to understand the evolution of the human species and the relationships among contemporary and extinct populations.  We talk about the Polymerase Chain Reaction (PCR), detecting sequence and length polymorphism, how DNA tests are used to identify individuals in forensic investigations, how they can be used to track relationships among human populations both ancient and contemporary, and how what we've learned using this technology may help us grow bigger, better, faster brains in our science fictional future.Email: thescienceinthefiction@gmail.comFacebook: https://www.facebook.com/groups/743522660965257/

It could be argued that biology has always boiled down to chemistry, and that chemistry has always boiled down to physics. However, not many would deny that the fields of biology and chemistry are overlapping more than ever, with both leveraging computing methods, also more than ever. This conversation with Dr. Ramesh Jha, Technical Staff Member at Los Alamos National Laboratory (LANL), crosses biology, chemistry, and computing methods. The work of his biome team at LANL uses computational tools to inform the design of enzymes that are produced via PCR-based cloning and then expressed in microbes. They use fluorescent gene circuits in these microbes, along with flow cytometry, to screen these large libraries for advantageous gain-of-function variants. When they find an interesting mutation, they isolate it, sequence it, and produce and evaluate those biocatalytic enzymes for bioremediation, biomanufacturing, and other important applications. Ramesh makes this complex and interdisciplinary science approachable and gives hope to how it could help address problems of “forever chemicals” and other environmental and manufacturing challenges. Join us for this interesting and inspiring conversation.  Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into the characteristics, detection, and treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. The podcast discusses recent advances, the efficacy of various treatments including small molecule tyrosine kinase inhibitors and monoclonal antibodies, and the potential future of targeted therapies. Special focus is given to the Phase 3 Papillon study and the drug Amivantamab, highlighting the need for next generation sequencing in clinical settings. Key challenges and questions in the field are also addressed, including the impact of co-mutations and optimal therapy sequencing.This episode is sponsored by: Johnson & Johnson(00:00) Introduction and Acknowledgements(00:48) Introducing the Experts(01:29) Understanding EGFR Exon 20 Insertion Mutations(05:04) Challenges with Current Treatments(06:30) Emerging Therapies and Clinical Trials(11:03) Papillon Study Insights(21:27) Future Directions and Unanswered Questions(29:34) Conclusion and Final Thoughts

Genetische Erkrankungen sind aufgrund ihrer sehr vielfältigen Ausprägung und vor allem ihrer Seltenheit schwer zu diagnostizieren. Dabei ist eine rasche Diagnose nicht nur für die Lebensqualität wichtig, sondern sie kann auch eine Rolle in der Familienplanung spielen. Sarah Verheyen von der Med Uni Graz kommt den seltenen genetischen Erkrankungen mittels Genomanalyse auf die Spur.  Dr. Sarah Verheyen. ist ist die ärztliche Leiterin des sogenannten „Exom"-Diagnostik-Teams für Seltene Erkrankungen an der Med Uni Graz. Das Exom umfasst etwas mehr als 20.000 Gene, die dafür verantwortlich sind, den Bauplan für Proteine bereitzustellen. Bei der Exomanalyse werden diese Gene untersucht, um Fehler zu finden, die eine Erkrankung hervorrufen können. Bei einer Genomanalyse wird hingegen das gesamte Erbgut durchleuchtet. Zum Vergleich: Das Exom stellt in Sachen „Datenmenge“ etwa 2 % des Genoms dar. Moderne Analysemethoden ermöglichen es mittlerweile, diese Unmengen an Daten zu verarbeiten. Die Analysemethoden, die bei der Genomanalyse verwendet werden, erlauben es in manchen Fällen auch, Veränderungen im Exom besser aufzuspüren. „Wir setzen Next Generation Sequencing ein. Das ist eine Methode, mit der man sehr viele Daten gleichzeitig generieren kann." Im Unterschied zur herkömmlichen Methode, bei der auf Verdacht einzelne Gene angeschaut wurden und die Patienten mitunter jahrelang auf ihre Diagnose warten mussten, sei es heute möglich, „in 1,5 bis 2 Wochen eine Diagnose zu erhalten", sagt Verheyen. Trotzdem komme man nur in ein Drittel der Fälle auf eine Diagnose, weil viele seltene Erkrankungen nach wie vor ungeklärt seien. Konkret könne man nur einem Viertel der Gene  eine Krankheit zuordnen. Es bestehe noch viel Forschungsbedarf. Schön und herausfordernd zugleich, so beschreibt Verheyen ihre Arbeit. Vor allem, wenn, wie so oft, Kinder involviert sind. Auch hier biete die moderne genetische Diagnostik neue Wege, um schwerwiegenden Problemen schnell auf die Schliche zu kommen. Invasive Diagnostik und lange Wartezeiten würden so vermieden.

“Under normal conditions, EGFR [epidermal growth factor receptor] is in an auto-inhibited state. And it's only when it's needed that it's upregulated. But when you have cancers that there is either a mutation in the EGFR or an overexpression, what you see is a dysregulation of normal cellular processes. So you get overexpression or switching on of prosurvival or antiapoptotic responses,” Rowena “Moe” Schwartz, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the EGFR inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to EGFR inhibitor drugs. Episode Notes  Complete this evaluation for free NCPD.  Oncology Nursing Podcast™ episodes: Pharmacology 101 series Episode 250: Cancer Symptom Management Basics: Dermatologic Complications Episode 226: Patient Education for Next-Generation Sequencing to Guide Cancer Therapy Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Management Strategies for Cutaneous Toxicity From EGFR Inhibitors Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Osimertinib Oncology Drug Reference Sheet: Panitumumab Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (Fourth Edition) ONS courses: ONS Cancer Biology™ ONS/ONCC Chemotherapy Immunotherapy Certificate™ Safe Handling Basics Clinical Journal of Oncology Nursing articles: Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices Medication Adherence Barriers: Development and Retrospective Pilot Test of an Evidence-Based Screening Instrument ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity Nursing Management of Skin Toxicities in Diverse Skin Tones ONS Bispecific Antibody Video ONS Learning Libraries: Genomics and Precision Oncology Oral Anticancer Medication Oral Chemotherapy Education Sheets Seminars in Cancer Biology article: EGFR signaling pathway as therapeutic target in human cancers To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “It wasn't until 2004 that the mutations affecting the tyrosine kinase domain of epidermal growth factor receptor was linked to the responses that were seen in gefitinib. And that's when we really started to understand the way that this was targeting certain patients' cancers. So that led to the phase three study. People may remember the IPASS study that demonstrated that when patients had an activating mutation of EGFR, that that was a really good biomarker that selected out patients that would respond to therapy.” TS 2:58 “The new player on the market is the bispecific. … This was a bispecific that was developed to hit two different targets. The one target is EGFR. The second target was MET. And the reason MET was targeted is because when you have patients who are on EGFR tyrosine kinase inhibitors, they do so well. But over time, resistance develops. And one of the mechanisms that are thought to be important for resistance is that MET pathway. So it was a development of a bispecific antibody that hit two different targets, EGFR and MET, hoping that you would get less resistance.” TS 7:12 “The other thing that I see with these agents is seeing them combined with chemotherapy. For a long time, it was these drugs were used as the single approach to someone with non-small cell lung cancer who had an EGFR mutation, and they did well. But I think we're starting to see that because resistance does develop, that there may be roles for combination with chemotherapy, and you're seeing that in terms of drug approval.” TS 19:10 “I think that people that don't work in the clinic, say, with non-small cell lung cancer—they think of these as a group and don't realize the uniqueness of specific agents, what mutations that they hit that affected those that penetrate into the [central nervous system], the drug interactions that are specific for certain agents. So I think that's one of the common misconceptions.” TS 22:02 “The education, because it evolves so rapidly, is to realize that what you know, if it's from a year ago, may not be the full picture. And so again, I'm going to call out ONS for the phenomenal resources on the Genomics and Precision Oncology Learning Library to help providers learn. And that is updated, and it is readily available. I think it is phenomenal, and I think it helps people build on their basic understanding of any of these types of therapy, including EGFR inhibitors.” TS 23:24

Dr. Jonathon Hill, VP of Science and Technology and Co-Founder of Wasatch Bio Labs has developed the Next-Generation Sequencing 3.0, NESSI-Seq platform, which can analyze blood to detect epigenetic changes and provide insights into current health and predisposition for diseases. This native-read third-generation sequencing tool can provide longer sequence reads and analyze epigenetic modifications to DNA. Epigenetics can change over time in response to diet, environment, and lifestyle. Advanced genetic testing has the potential to provide biomarkers to support personalized medicine for earlier detection and tailored interventions. Jonathon explains, "The biggest limitation with the Illumina sequencing was that it was only short sequences, so you had to get a lot of them to stitch them together and figure out what the human genome looked like. With this third-generation sequencing, we can get much longer reads, sometimes to the order of a hundred thousand nucleotide bases at a time. So we get these big complex reads." "The other thing we can do now with this third-generation sequencing is look at certain chemical modifications the body makes to the DNA to help regulate that DNA and help the body function. And looking at those chemical modifications can tell us a lot about someone's health. It can tell us their age, and it can tell us what disease they might have. We can get a lot of information out of that that just wasn't available to us in the previous two generations."  "If you think of classical genetics, it's the DNA sequence and the mutations you might have that might give you a propensity for the disease, etc. Those don't change throughout your life. Every cell in your body has that exact same sequence from birth until death. It never changes. But the epigenetics, these chemical modifications change. They change as you age. They are different in different tissues and organs within your body, changing even in response to pathogens or certain disease states. So they have a lot of information that we would not get otherwise." #WasatchBioLabs #Epigenetics #GeneticResearch #PersonalizedMedicine #DNAInnovation #GeneticTesting #NextGenSequencing #BiotechBreakthroughs #GeneRegulation #HealthcareInnovation #FutureofMedicine Wasatchbiolabs.com Download the transcript here

Dr. Jonathon Hill, VP of Science and Technology and Co-Founder of Wasatch Bio Labs has developed the Next-Generation Sequencing 3.0, NESSI-Seq platform, which can analyze blood to detect epigenetic changes and provide insights into current health and predisposition for diseases. This native-read third-generation sequencing tool can provide longer sequence reads and analyze epigenetic modifications to DNA. Epigenetics can change over time in response to diet, environment, and lifestyle. Advanced genetic testing has the potential to provide biomarkers to support personalized medicine for earlier detection and tailored interventions. Jonathon explains, "The biggest limitation with the Illumina sequencing was that it was only short sequences, so you had to get a lot of them to stitch them together and figure out what the human genome looked like. With this third-generation sequencing, we can get much longer reads, sometimes to the order of a hundred thousand nucleotide bases at a time. So we get these big complex reads." "The other thing we can do now with this third-generation sequencing is look at certain chemical modifications the body makes to the DNA to help regulate that DNA and help the body function. And looking at those chemical modifications can tell us a lot about someone's health. It can tell us their age, and it can tell us what disease they might have. We can get a lot of information out of that that just wasn't available to us in the previous two generations."  "If you think of classical genetics, it's the DNA sequence and the mutations you might have that might give you a propensity for the disease, etc. Those don't change throughout your life. Every cell in your body has that exact same sequence from birth until death. It never changes. But the epigenetics, these chemical modifications change. They change as you age. They are different in different tissues and organs within your body, changing even in response to pathogens or certain disease states. So they have a lot of information that we would not get otherwise." #WasatchBioLabs #Epigenetics #GeneticResearch #PersonalizedMedicine #DNAInnovation #GeneticTesting #NextGenSequencing #BiotechBreakthroughs #GeneRegulation #HealthcareInnovation #FutureofMedicine Wasatchbiolabs.com Listen to the podcast here

In dieser Folge des ERCM Medizin Podcasts ist Prof. Dr. Dr. Torsten Haferlach, mein Gast, einer der führenden Hämatoonkologen und Leukämie-Spezialisten Deutschlands, sowie ein Experte für Künstliche Intelligenz in der Medizin. Prof. Haferlach ist Mitgründer des Münchner Leukämielabors (MLL), das in den letzten 20 Jahren zu einem der führenden Institute im Bereich hämatologische Diagnostik avancierte. Die zunehmende Digitalisierung bringt massive Datenmengen mit sich – insbesondere in der Medizin. Skalierbare KI-Systeme bieten enorme Chancen, die Gesundheitsversorgung nachhaltig zu verbessern. Was vor einigen Jahren wie eine Zukunftsvision schien, ist in vielen Bereichen heute Realität. Insbesondere im Bereich der Onkologie führt die Kombination aus medizinischer Bildanalyse und KI-gestützter Diagnostik zu einer beispiellosen Präzision und Geschwindigkeit in der Diagnosestellung. Gemeinsam sprechen wir darüber, wie verantwortungsvoll eingesetzte KI zu einer patientenzentrierten, individuellen Versorgung der Zukunft beitragen kann und wie die „digitale Patienten-Reise“ unser Gesundheitssystem verändert. "Der ERCM Medizin Podcast" Social & Webseite Instagram: https://www.instagram.com/ercm.podcast/ TikTok: https://www.tiktok.com/@ercm.podcast?lang=de-DE X (Twitter): https://twitter.com/ERCMPodcast Webseite: www.erc-munich.com Kontakt: podcast@erc-munich.com Prof. Dr. Dr. Torsten Haferlach Webseite: https://www.mll.com/ LinkedIn: https://www.linkedin.com/company/mll-muenchner-leukaemielabor/ Facebook: https://www.facebook.com/muenchnerleukaemielabor/ Instagram: https://www.instagram.com/muenchnerleukaemielabor/ Zeitangaben 00:00 – Einführung und Vorstellung von Prof. Dr. Dr. Haferlach 00:46 – Karriereweg und besondere Interessen von Prof. Haferlach 03:19 – Fortschritte in der Diagnostik 05:38 – Einsatz von KI in der Diagnostik 07:42 – KI-Anfänge im Münchner Leukämielabor 11:08 – KI in der medizinischen Bildanalyse 16:11 – KI und autonome Diagnostik 20:02 – Empathie vs. KI in der Medizin 26:01 – Deutsche Sicht auf Digitalisierung und KI 30:32 – Next Generation Sequencing erklärt 37:42 – Therapien und KI-gesteuerte Prognosen 43:18 – Genetische Prävention und Sequenzierung 52:16 – Digitale Infrastruktur und Cloud-Systeme 01:04:00 – KI-gestützte Befundschreibung 01:09:00 – Ausblick: KI-Zukunft in der Medizin Hashtags #ki #künstlicheintelligenz #leukämie #gesundheit #medizin #kiinmedizin #gesundheitswesen #Onkologie #MedizinPodcast #ercmpodcast

In this JCO Precision Oncology Article Insights episode, Miki Horiguchi summarizes an editorial: “Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of JCO Precision Oncology” by Dr. Yushu Shi et al. published on May 30, 2024. TRANSCRIPT Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Miki Horiguchi, an ASCO Journals Editorial Fellow. Today, I will be providing a summary of the article titled “Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of JCO Precision Oncology”. This is an editorial by Dr. Yushu Shi and colleagues that investigated trends in publication, peer review, and global influence of JCO precision oncology. Before getting into the editorial, I would like to briefly introduce to precision oncology and the JCO Precision Oncology journal as a leading platform for research in this field. Precision oncology is a personalized medicine approach that leverages advances in genomics and molecular profiling of tumors, biomarker-driven decisions, and targeted therapies to enhance clinical care for patients with various cancer types. Since there are many aspects to consider, such as biologic, clinical, and statistical aspects, advances in precision oncology also come with numerous challenges. These include identifying targetable mutations and addressing tumor heterogeneity and drug resistance. Other challenges are developing new study designs and statistical analysis methods to evaluate new approaches, as well as developing methods to manage large and complex datasets.  Since the American Society of Clinical Oncology introduced the journal JCO Precision Oncology (or JCO PO) in 2016, it has played an important role as a dedicated platform for publishing high-quality research and promoting discussions on those challenges. JCO PO is a peer-reviewed, online-only, article-based journal publishing articles across multiple categories. These include original reports, case reports, review articles, commentaries, correspondence, editorials, special articles, and molecular tumor board case discussions. The journal's contribution to the advancement of the field is reflected in the journals' impact factor, which was 4.6 in 2022 and 5.3 in 2023.  In the editorial, Dr. Shi and colleagues first investigated the publication trends from 2017 to 2022, highlighting cancer types, article types, the number of citations, and topics of papers published in JCO PO that have had broad impact. The papers accepted at JCO PO covered a broad range of research topics, including genomics-driven tumor treatments, molecularly selected targeted therapy, translational oncology, cancer biomarkers, gene expression and profiling, biostatistics and clinical trial methodology, epidemiology, and cancer prevention and control. The most common cancer types are thoracic, GI, and breast cancers. Original reports were more likely to be cited than case reports. The average number of annual citations for original reports was 4.33, while it was 1.39 for case reports. The authors listed the 10 most cited papers published in JCO PO in a table. The most cited paper was an original report titled “Landscape of Microsatellite Instability Across 39 Cancer Types” by Bonneville and colleagues. The paper has been cited more than 600 times since it was published in 2017.   Next, the authors conducted an analysis to see trends in peer-review. When manuscripts are submitted to JCO PO, they go through a rigorous peer-review process. Reviewers evaluate them based on five key metrics: importance of the study, originality, quality of writing, relevance to clinical practice, and scientific strength. Each metric is rated on a scale from 1 to 5, with higher scores indicating better performance. Dr. Shi and colleagues compared the rating scores between accepted and rejected manuscripts of original reports and case reports. They found that the median score of accepted manuscripts was above 3.5 for all metrics. The findings highlight that no single metric determines acceptance, underscoring the importance of excelling in all five areas when developing manuscripts. Finally, the authors looked at trends in global influence in JCO PO. Counting the country where the corresponding author's institution is located, Dr. Shi and colleagues found that JCO PO has accepted manuscripts from 36 countries, indicating a steady increase in its global reach. The United States accounts for about 71% of the total contributors. The other top contributors include France, Canada, Italy, Australia, the Netherlands, Germany, Japan, the United Kingdom and China. Notably, global collaborations among authors have significantly increased, with the proportion of papers from multiple countries more than doubling from 12.5% in 2016 to 26.5% in 2022. These facts reflect JCO PO's ongoing commitment to engaging with the international precision oncology community and encouraging global research submissions. At the end of the editorial, the authors provided some guidance for future authors. Across original reports and case reports, successful submissions to JCO PO typically have a translational focus. They provided a mechanistic understanding of tumor biology and utilized cancer genomics to inform clinical decision making. The authors also highlighted several underrepresented but growing areas of interest at JCO PO. These include pediatric oncology, sarcomas, ethics, trial methodology, informatics, computational approaches, and statistical methods related to precision oncology. Furthermore, the increasing significance of germline genetics, pharmacogenetics, molecular diagnostics, and molecular epidemiology in precision oncology has been recognized and valued by JCO PO. JCO PO also has special series issues. The special series feature timely research topics, such as Equity in Precision Medicine, Statistical Methods for Precision Oncology, and Next Generation Sequencing. Through these special series, JCO PO continues to lead the advancement of the application of precision oncology across a diverse patient population. The authors also provided points to consider when submitting case reports. For successful case report submissions, especially n-of-1 reports that showcase novel findings with potential clinical impact, it is crucial to include robust data to support the clinical observations, investigate underlying mechanisms, and ensure proper protection of patients' identity and autonomy. An n-of-1 report alone is often insufficient for publication. Successful case reports typically extend beyond a single patient, examining the phenomenon in multiple patients and providing mechanistic validation, either in vitro or through preclinical models. Thank you for listening to JCO Precision Oncology Article Insights and please tune in for the next topic. Don't forget to give us a rating or review and be sure to subscribe, so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.  

Unlock the future of epigenetics and join us for an insightful conversation with Jonathon Hill as he delves into the groundbreaking world of next-generation sequencing (NGS) and its transformative impact on science and medicine. Jonathon Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physiology at Brigham Young University.Discover how cutting-edge nanopore technology is overcoming the limitations of traditional methods and revolutionizing epigenetic research.Key Takeaways:Unparalleled Accuracy: Learn how nanopore technology achieves 99.6% accuracy in methylation calls, eliminating PCR and bisulfite conversion noise.Comprehensive Insights: Understand the benefits of whole-molecule sequencing for detailed methylation analysis, providing a clearer, more precise picture of genetic data.Future of Diagnostics: Explore the future of NGS in clinical settings, with genomic and epigenetic data integration into electronic health records guiding personalized treatments.Don't miss this episode packed with innovative insights and the future landscape of genomic technology.Connect with Jonathon Hill:LinkedIn: https://www.linkedin.com/in/jonathon-t-hillWasatch BioLabs: https://www.wasatchbiolabs.comNext Steps:Schedule your free assessment to take process development to the next level now at https://bruehlmann-consulting.com/assessment

Curious about the latest advancements in next-generation sequencing (NGS) and how they are revolutionizing science and medicine?In this episode, we delve into the cutting-edge developments of NGS with our expert guest, Jonathon Hill, VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physiology at Brigham Young University, who has been at the forefront of this transformative field.Key Takeaways:Discover how NGS is empowering scientists to explore new frontiers in research with groundbreaking tools and technologies.Learn about the incredible advancements in long-read sequencing and their impact on genome assembly and understanding complex diseases.Understand how NGS is unlocking the potential of epigenetics, revolutionizing drug development, and enhancing diagnostic accuracy for personalized medicine.Join us to get an insider's view on how NGS is not only changing the landscape of research but also making a profound impact on human health. Don't miss this informative conversation with a leading expert in the field!Connect with Jonathon Hill:LinkedIn: https://www.linkedin.com/in/jonathon-t-hillWasatch BioLabs: https://www.wasatchbiolabs.comNext Steps:Schedule your free assessment to take process development to the next level now at https://bruehlmann-consulting.com/assessment

Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare cancers. Sanjeev explains, "There's a pathway that is very important for the growth of cancer cells. This is proliferation, motility, migration, and invasion of cancer cells, and that's the thematic pathway. This is an important receptor, which is upstream in cell signaling of these cancer cells. This is when these pathways work well, these cells grow as normal homeostasis, normal growth of cells. When this pathway is disrupted in cancer cells, they tend to grow far more than what normal cells would. That's the pathway that we are going after. These are mutations in this pathway, in the genome amplification, gene amplification, and fusions, which lead for these particular cancers to grow well. If you are able to inhibit that pathway, then you are able to impart benefit to the patient. And that's what one of our main drugs, Vebreltinib, is going after." "As a whole, in lung cancer, even though the checkpoint inhibitors have moved the needle in terms of five-year survival rates, the needle has been moved from about 25% to about 30%, 32%, which is still much lower than say breast cancer, prostate cancer, where the five-year survival rates are close to 80%, 90%. So, how we can win the battle against lung cancer and brain cancer is really using precision-targeted therapies. These slivers of cancers that have a particular mutation, that have a particular dysregulation, and having treatments for that allow these patients a targeted approach for a longer benefit as opposed to one treatment for the entire lung cancer population. That is why we go after the so-called slivers, which put them into the rare cancers bucket." #Apollomics #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling #AI Apollomics.com Download the transcript here

Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare cancers. Sanjeev explains, "There's a pathway that is very important for the growth of cancer cells. This is proliferation, motility, migration, and invasion of cancer cells, and that's the thematic pathway. This is an important receptor, which is upstream in cell signaling of these cancer cells. This is when these pathways work well, these cells grow as normal homeostasis, normal growth of cells. When this pathway is disrupted in cancer cells, they tend to grow far more than what normal cells would. That's the pathway that we are going after. These are mutations in this pathway, in the genome amplification, gene amplification, and fusions, which lead for these particular cancers to grow well. If you are able to inhibit that pathway, then you are able to impart benefit to the patient. And that's what one of our main drugs, Vebreltinib, is going after." "As a whole, in lung cancer, even though the checkpoint inhibitors have moved the needle in terms of five-year survival rates, the needle has been moved from about 25% to about 30%, 32%, which is still much lower than say breast cancer, prostate cancer, where the five-year survival rates are close to 80%, 90%. So, how we can win the battle against lung cancer and brain cancer is really using precision-targeted therapies. These slivers of cancers that have a particular mutation, that have a particular dysregulation, and having treatments for that allow these patients a targeted approach for a longer benefit as opposed to one treatment for the entire lung cancer population. That is why we go after the so-called slivers, which put them into the rare cancers bucket." #Apollomics #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling #AI Apollomics.com Listen to the podcast here

Dr. Stacey Clardy talks with Dr. Charles Chiu to discuss his paper "Pathogen Detection and Associated Patient Characteristics from Clinical Metagenomic Next-generation Sequencing Testing for Neurological Infections."  Show reference:  https://index.mirasmart.com/AAN2024/PDFfiles/AAN2024-002889.html

To learn more about BCLA's events and consulting visit https://www.bc-la.org/Complete Genomics: https://www.completegenomics.com/company/about-us/Joyee Yao's LinkedIn: https://www.linkedin.com/in/joyee-yao-74901212/ To learn more about BCLA's events and consulting visit https://www.bc-la.org/

BUFFALO, NY- February 28, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.” In this new exploratory and descriptive study, researchers Elisabetta De Matteis, Maria Rosaria Tumolo, Paolo Tarantino, Mariangela Ciccarese, Tiziana Grassi, Francesco Bagordo, Maria Rita De Giorgio, Emanuele Rizzo, and Graziana Ronzino from Vito Fazzi Hospital, University of Salento, Strategic Regional Agency for Health and Social of Puglia, and University of Bari Aldo Moro aimed to characterize the deleterious BRCA1 and BRCA2 variants evaluated by genetic testing in a group of Ovarian cancer patients living in the Salento peninsula (Southern Italy). From June 2014 to July 2023, patients with histologically confirmed high-grade serous carcinoma, fallopian tube, or primary peritoneal cancer who were referred to Lecce Familial Cancer Clinic were considered. BRCA-mutation genetic testing was performed on these patients. Socio-demographic data and cancer epidemiology were assessed, and Next Generation Sequencing and Sanger DNA sequencing were performed. The median age at the diagnosis of 332 ovarian cancer patients collected was 57 years. The pedigree analyses showed that 28.6% had familial cases and 39.7% had sporadic cases. Of the 319 patients submitted to genetic testing, 29.8% were carriers of BRCA1/2 mutation, 75.8% at BRCA1 and 24.2% at BRCA2 gene. Of the 21 BRCA1 mutations, the variant c.5266dupC was the most frequent alteration (28.4%). With respect to BRCA2, 13 mutations were found and the variant c.9676delT was the most frequently recorded (6.3%). “This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.” DOI - https://doi.org/10.18632/oncotarget.28561 Correspondence to - Maria Rosaria Tumolo - mariarosaria.tumolo@unisalento.it Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28561 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, ovarian cancer, BRCA1, BRCA2, mutation About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

The field of Microbiology continues to change. Organisms were primarily identified in the clinical laboratory by biochemical testing. Then MALDI-TOF came to the lab and was incorporated to the workflow. Now labs are bringing next-generation sequencing (NGS). What is NGS? How does it work? Have you heard of Nanopore technologies? In this episode Dr. Jose Alexander and Daniel Navas from Advent Health Orlando, join the podcast to talk about NGS. They brought it to their laboratory and discuss the whole process, including the validation, challenges and more.Have any feedback or suggestions? Send those to letstalkmicro@outlook.com

Host Dr. Joseph Patterson interviews paper author Dr. Roman Natoli. This paper was presented at the 2023 OTA Annual Meeting. To see the abstract while you listen, download the free ConveyMED app: Apple Store click here Google Play click here  Thank you to Stryker for sponsoring this episode. For more information on the Stryker Alliance program visit https://alliancecanhelp.com . To listen to the podcast: "Help Them Help You: Creating Orthopaedic Trauma Value Through a Hospital Alliance," download the ConveyMED app for free and listen: https://share.conveymd.com/b1ro86mQDnqBBkA28 . To listen on Apple podcasts: https://podcasts.apple.com/us/podcast/help-them-help-you-creating-orthopaedic-trauma-value/id1505387332?i=1000621492861 , or on Spotify: https://open.spotify.com/episode/6lmYIBZo5A5YpxGK86Krxr?si=zx9CloCNRkG68o9J_cCtYw  For additional educational resources visit https://ota.org/ 

When I first read Fabio's profile I was rather suspicious. A genetist in the agave realm? Isn't the point to just leave agave alone to be glorious and genetically diverse? Well, turns out that Fabio does a significant number of great ideas to continue the centuries-old-interaction between agave and humans. Here is Fabio's profile on his own words. You can find him in LinkedIn as Fabio Raya:I'm BA in Biotechnology (UFSCar at Araras) and MSc. in Genetics and Molecular Biology (Unicamp). I've worked with Next-Generation Sequencing at the Integrated Genomics Cores (HTSF - UNC at Chapel Hill), one of the largest sequencing facilities in the US. In 2017, I've founded ECRA Biotech, a synthetic biology start-up that develops and manufacture kits for diagnostics and genetic engineering. There, I've worked on the development of more than 15 biotechnological products for research and molecular diagnostics, including RNA/DNA extraction kits, DNA polymerases, reverse transcriptases, and other specialties enzymes.At Unicamp, I'm a Ph.D. candidate, also in Genetics and Molecular Biology, and the curator of the "Germplasm Bank for Climate Change". My research work focuses on Agave, plant biotechnology, plant breeding, bioeconomy, and biorenewables production in semiarid regions.

Was hat die Züchtung von Rennpferden mit dem Abwasser-Monitoring von Viren gemeinsam? In der heutigen Folge widmet sich Prof. Dr. Joachim Schultze (DZNE) dem Thema der Next Generation Sequencing Technologien. Wie funktionieren sie und was kam eigentlich davor? Zusammen betrachten wir, in welchen spannenden Bereichen NGS eingesetzt wird und was in Zukunft noch alles denkbar ist.

Today's guest is Varun Dwaraka, Head of Bioinformatics at TruDiagnostic in Lexington, Kentucky. Founded in 2019, TruDiagnostic are on a mission to help people understand, access and benefit from their epigenome. TruDiagnostic are home the largest, private epigenetic database in the world and are leading the way in DNA methylation-based research and discovery. As they continue mapping unforged health information found in the fluid epigenome, the company combine data and AI to develop new methylation-based diagnostic tools. Varun is an experienced scientist with proven experience in the development of Next Generation Sequencing and array based analytical pipelines using univariate, multivariate and Machine Learning methods. He is also an effective communicator, presenting at international and national conferences in poster presentations and talks, while also publishing in international, peer reviewed journals. Varun is passionate about learning and implementing ML methods to advance predictive medicine and advance our understanding in the biology of aging.  In the episode, Varun will discuss: Their mission at TruDiagnostic, His role working with Regression Modelling & Deep Learning, How his Bioinformatics team collaborates with Data Science, Upcoming projects that excite him, Why TruDiagnostic is a great place to work

On this episode, we talked with Mr. John Sadowski, the Lead Technologist at UPMC for Next-Generation Sequencing (NGS). Mr. Sadowski performed beta testing of the Oxford Nanopore System for HLA sequencing and he walks us through how nanopore sequencing works and names the advantages and disadvantages compared to other sequencing methods.

Episode Description: In this episode of Grow Everything, Karl and Erum are joined by Nili Ostrov, co-founder of Cultivarium, as they explore the fascinating world of biotechnology. They discuss the challenges of working with new organisms, the importance of community in biotech, and the need for resources to be available for non-model microbes. The conversation delves into the potential of mycology, the importance of next-generation sequencing technology, and the benefits of diversifying the catalog of organisms used in scientific research. They also touch on biosecurity concerns, the democratization of biotech, and the potential applications of biotechnology in various fields. The episode concludes with book recommendations that encourage diversity and exploration in the field of biotechnology. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space.  Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00:00 - Luminescent Hair: Unleashing New Possibilities with Non-Model Organisms 00:01:21 - Surprises in Biotech: Highlights from Simba Beta Conference 00:06:27 - From Computer Scientist to Organ Transplant Pioneer: The Inspiring Journey of Martine Rosenblatt 00:12:31 - Redefining Biotech: Evolution and Transformation in the Industry 00:15:31 - Exploring Non-Model Organisms: Unveiling the Wonders with Nili from Cultivarium 00:18:45 - Next Generation Sequencing and Plasmids: Revolutionizing Biotech 00:22:49 - Cultivarium: Revolutionizing Biotechnology with Non-Model Organisms 00:25:30 - Streamlining Microbe Onboarding: Faster and Cost-Efficient Biotech Breakthroughs 00:29:05 - Open Source Tools in Microbial Research: Empowering Scientists Everywhere 00:30:38 - Driving Change in Biotech: Cultivarium's Impact on the Industry 00:34:38 - Unleashing Microbes' Potential: Key Achievements for Biotech Applications 00:42:25 - Organisms Unleashed: Readiness for Industry and Lab Use 00:43:31 - Troubleshooting Community: Simplifying Host Selection for Biotech Applications 00:48:51 - Importance of Hands-On Lab Work in Functional Genomics: Insights from Nili Ostrov 00:50:51 - Tigers to E. Coli: Technological Advancements in Studying Organisms 00:53:03 - Superpowers of Extremophiles: Microbes' Role in Climate Change Solutions 00:57:21 - Unveiling the Microbial World of NYC Subway: Resistant Microbes and Macros 00:58:53 - Exploring Microbial Treasures for Sustainable Solutions 01:03:56 - Non-Model Organisms: Revolutionizing Biotech with Nili Ostrov 01:12:39 - Non-Model Organisms in Hair Care: Exciting Possibilities Episode Links: Cultivarium Nili Ostrov on LinkedIn Lanzatech - carbon emissions into products Lanzatech & Adidas Jacket Lanzatech & H&M Jumpsuit Mycomedica - mushroom therapeutics by Paul Stamets Call or Text the Grow Everything Hotline:  +1 804-505-5553 Have a question or comment? Message us here: Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:Expression patterns and function of the claudin family of proteins in normal gastric tissuesBiologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncologyPrognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancersLaboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selectionFuture directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructsPresenters:Samuel Klempner, MDAssociate ProfessorDepartment of MedicineDivision of Hematology-OncologyMass General Cancer CenterHarvard Medical SchoolBoston, MassachusettsGregory Botta, MD, PhDClinical Professor of MedicineDepartment of MedicineDivision of Hematology & OncologyUniversity of California San DiegoLa Jolla, CaliforniaContent for this program was supported by educational grants from Astellas and Bristol Myers Squibb.Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):bit.ly/3lQxPrq

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts' thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:  Practical use of the Molecular International Prognostic Scoring System  Mutational targets and other treatments in ongoing clinical trialsProphylaxis with venetoclax therapyBest practices for bone marrow transplant, including induction and salvage regimensTreatment options for hypoplastic myelodysplastic syndromesPresenters:Rami Komrokji, MDProfessorDepartment of Oncologic SciencesUniversity of South Florida  Vice ChairMalignant Hematology DepartmentMoffitt Cancer CenterTampa, FloridaMaría Díez Campelo, MD, PhDAssociate ProfessorDepartment of MedicineSchool of MedicineUniversity of SalamancaHematologistDepartment of HematologyUniversity Hospital of SalamancaSalamanca, SpainAmer Zeidan, MBBS, MHSAssociate Professor, Internal MedicineHematologyLeader, Leukemia and Myeloid Disease Aligned Research Team (DART)Director, Hematology Early Therapeutics ResearchYale Cancer Center and Smilow Cancer HospitalYale University School of MedicineNew Haven, ConnecticutLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:http://bit.ly/3YXgKK3  

In her book 'Advancing Healthcare Through Personalized Medicine', science writer Dr Priya Hays has compiled an authoritative and highly detailed account of how technology is changing healthcare. Read more in Research FeaturesRead it now at :https://doi.org/10.1007/978-3-030-80100-7 

In what we hope is the late phase of the COVID-19 pandemic, we'll take a look at other long-running issues relating to health care, healthy living, and access to care for the LGBTQ+ community. Our expert panelists for this discussion are leaders in the efforts to reach LGBTQ+ people, informing them and connecting them to appropriate health care services. About the Speakers Dr. Monica Ghandi, M.D., M.P.H., was a recipient of The Commonwealth Club's Distinguished Citizens Award in 2021. She is an infectious diseases doctor, professor of medicine and associate chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the director of the UCSF Center for AIDS Research (CFAR) and the medical director of the HIV Clinic ("Ward 86") at San Francisco General Hospital.  Craig Rouskey is the co-founder and CEO of Renegade.bio. Rouskey was also a co-founder and CSO at Pando Nutrition, an animal nutrition company. At Avant Immunotherapeutics, he worked on vaccine projects against avian influenza (H5N1) and anthrax. He co-founded the Gonorrhea Eradication Team (GET) and served as principal scientist for the Immunity Project, creating an open source vaccine against HIV. Rouskey has also served as a scientist in the Antibody Therapy Group at Novartis and in product development with the Next Generation Sequencing group at Thermofisher. Antwan Matthews, BS, serves as director of youth programs at Code Tenderloin and is a consultant. A leader in the community, he previously served as a LINCS Navigator with the San Francisco Department of Public Health. He has been an advocate on many issues connected to the National AIDS Memorial, having served on its board of directors and being a recipient of the Pedro Zamora Youth Scholarship. His work includes being a sexual and reproductive health advocate who cares deeply about the physical, emotional, and psychological health of individuals globally, especially the Black community. His career includes working at Glide and Peer HEALTH Educators. His work today continues around supporting, educating, advising, teaching, and healing people receiving health care impacted by the history of medical abuse inflicted on communities of color. Antwan uses his voice to raise issues about health and social justice. You can read some of his work here.  Dr. Alexis Petra, M.D. is the founder and CEO of TransClinique. Petra was a practicing emergency medicine physician for more than 10 years prior to founding TransClinique. In 2019, she was named one of Phoenix magazine's Top Doctors in the Valley. Dr. Petra is board-certified in emergency medicine and licensed in more than 30 states. She is a member in good standing with WPATH. Petra has been personally and professionally involved in the transgender and non-binary community for more than 20 years. She founded TransClinique in April 2020 to give back to and create a safe space for members of the community to receive care. She provides hormone replacement therapy (HRT), letters of referral, and trans life coaching across the country through telemedicine. As a trans woman herself, Alexis understands the unique needs that members of this community have and knows firsthand both the hardships and rewards of the journey. Learn more at her website.  Learn more about your ad choices. Visit megaphone.fm/adchoices

We discussed a few things including the state of hard tech accelerators and the startup enviroment.Panelists included:Ela Jaworski, cofounder and CEO of XN Health, a HAX-backed venture (Newark).Laate Olukotun, cofounder/Chief of Product & Experience Design, InnerStill (NextFab, Philly)Justin Kosmides, cofounder and CEO of Vela Bikes, a tenant of Newlab (Brooklyn).Ela is passionate about bringing novel, promising new technologies to the market where she has over 9 years of experience researching and developing novel laboratory techniques and medical treatments. She is currently the co-founder and CEO of XN Health, a medical device startup developing a novel therapy intended to facilitate the weaning of mechanically ventilated patients by preventing and combating the progression of diaphragmatic atrophy. Prior to this venture, she helped develop a simple and affordable Next-Generation Sequencing library synthesis technology called ClickSeq and subsequently founded ClickSeq Technologies.Laate has designed and developed websites, apps, physical products, spaces, and experiences for a range of organizations including Steelcase, NextFab Foundation, and Mayo Clinic. He holds a BA in Economics from Yale University and a Master of Design from the Institute of Design at IIT. He runs the design agency Lollygig. He is also the Chief of Product & Experience Design and Co-Founder of Innerstill – a minority-owned, women-led enterprise launching wearable electroceutical products for restoring a sense of calm and increased feelings of wellbeing and inner fitness.Justin decided to pursue his passion for biking after a decade in the investment banking industry and tap into the changing world of mobility and electrical vehicles. Starting and scaling a brand during covid brought a long list of challenges but all of those have resulted in a resilient brand.

In this episode, guests Christine Ward, VP and Head of Oncology and Cell Therapy Precision & Translational Medicine at Takeda and Geoff Oxnard, Thoracic Oncologist and VP of Foundation Medicine talk to Patrick about Next Generation Sequencing (NGS) in precision oncology. Also covered are the impact of large-scale genetic datasets on patient diagnosis, data consortiums enabling pioneering discoveries, and the recent partnership between Takeda and Foundation Medicine.

In this episode, guests Christine Ward, VP and Head of Oncology and Cell Therapy Precision & Translational Medicine at Takeda and Geoff Oxnard, Thoracic Oncologist and VP of Foundation Medicine talk to Patrick about Next Generation Sequencing (NGS) in precision oncology. Also covered are the impact of large-scale genetic datasets on patient diagnosis, data consortiums enabling pioneering discoveries, and the recent partnership between Takeda and Foundation Medicine.

“Nurses can bridge the information gap and help patients better understand that the information received from next-generation sequencing (NGS) can really help to determine which treatment they will respond best to, if there are therapies that won't be effective, or if there are clinical trials that are open to them based on the results,” Danielle Fournier, RN, MSN, APRN, AGPCNP-BC, AOCNP®, CORLN, advanced practice RN in the department of thoracic surgery at MD Anderson Cancer Center in Houston, TX, told Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS. Fournier discussed the advancements being made in NGS technology and how it can be used to care for patients with cancer. This episode was produced by ONS and sponsored by Foundation Medicine. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. ONS Next-Generation Sequencing Toolkit, Sample Report, and Discussion Tool ONS Biomarker Database Oncology Nursing Podcast episodes: Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies Episode 172: Address Knowledge Gaps in Evidence-Based Precision Medicine Care Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: Oncology Nurses' Role in Translating Biomarker Testing Results Advocate for Equal Access for Next Generation Sequencing and Clinical Trials Help Patients Understand Genomic Variants of Unknown Significance How DNA Sequencing Technologies Are Used in Cancer Care, Now and in the Future ONS clinical practice resources: Biomarker Testing Quick Guide Biomarker Testing for Genomics Variants: What to Know From the Laboratory Performing the Test Paired Somatic and Germline Testing Resource The Oncology Nurse's Role in Somatic Biomarker Testing Biomarker Testing Nursing Process Understanding Genetic Variants Discussion Tool ONS Genomics Taxonomy ONS Genomics and Precision Oncology Learning Library International Society of Nurses in Genetics Position statement on informed consent National Comprehensive Cancer Network Guidelines National Comprehensive Cancer Network Biomarkers Compendium Information on Sanger sequencing Information on the Genetic Information Nondiscrimination Act Video series: Seq It Out To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we're learning that any given tumor may harbor a variety of variants. So, if we're considering using in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) to identify biomarkers, multiple assays may be needed and may need to be performed in order to test for multiple variants.” Timestamp (TS) 10:21 “There are multiple testing strategies that can be used with NGS technology, which is kind of what makes it so versatile. What type of testing is most appropriate really depends on the patient's risk factors, their diagnosis, their cancer stage, what testing has previously been completed, and what tissue is available for analysis.” TS 12:00 “Within oncology care, there is a role for NGS in the identification and management of both solid tumors and hematologic cancers, and this role is likely just going to continue to expand. So, really there's been an increased focus on genomic pharmacotherapy and targeted therapy, and this is playing an ever-greater role in the treatment of cancer. So, NGS will really continue to serve as a means to take a closer look at a patient's cancer at the molecular level and hopefully match patients with treatments that will be most effective at treating their cancer.” TS 20:54 “In reality, there's an expanding role for NGS testing in the diagnosis of many complex diseases. So, I think more than likely what we're going to see is that the indications and utility of NGS is only going to continue to grow in both the oncology setting as well as the non-oncology setting.” TS 23:08 “The oncology nurse really plays a key role in several important steps along the way. The first place they may be involved is in the informed consent process. Many—but not all—hospitals require patients to sign consent for genetic and genomic testing and this is just acknowledging that the patient is making an informed and autonomous decision related to their health care. Nurses may also play a role in the collection of a tissue sample or blood sample. And once testing has been completed, nurses may play a role in discussing the NGS results with patients.” TS 24:03 “Nurses really can help to somewhat bridge this information gap and help patients better understand that the information received from NGS can really help to determine which treatment they will respond best to, if there are therapies that won't be effective, or if there are clinical trials that are open to them based on the results. And these are all really important considerations for cancer treatment.” TS 36:21

Dr. Kenneth Taylor discusses his paper, "The Current Status of Next-Generation Sequencing for Diagnosis of Central Nervous System Infections". Show references: https://jamanetwork.com/journals/jamaneurology/article-abstract/2795620  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Celebrating those who enhance the ability to provide the right treatment for the right patient at the right time, the Cancer Community Awards sponsored by AstraZeneca presents an individual or organization with the Catalyst for Precision Medicine Award. We prepared for this year’s awards by reconnecting with the 2021 winner, Dr Colin Pritchard, to hear more about what’s happened since he received the award. 

Celebrating those who enhance the ability to provide the right treatment for the right patient at the right time, the Cancer Community Awards, sponsored by AstraZeneca, presents an individual or organization with the Catalyst for Precision Medicine Award. We prepared for this year’s awards by reconnecting with the 2021 winner, Dr. Colin Pritchard, to hear more about what’s happened since he received the award. 

In this podcast, our Medical Director, Brad Lewis, continues his conversation with Jamey Kain, Vice President of Genetic Innovation here at Machaon. Brad and Jamey discuss what next-generation sequencing (NGS) is, why it's important and some of the issues we face with NGS.Don't forget, Machaon offers genetic testing STAT results in 48 hours!

Dr Philip Smith, Digital and Education Editor of Gut and Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK, interviews Dr Maria Arechederra, young researcher at the Hepatology Program in the Center for Applied Medical Research (CIMA) from the University of Navarra in Pamplona, Spain, on the paper "Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures" which is published in paper copy in Gut in June 2022, and available online: https://gut.bmj.com/content/71/6/1141 Please subscribe to the Gut Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest podcast every month. If you enjoy our podcast, please consider leaving us a review or a comment on the Gut Podcast iTunes page (https://podcasts.apple.com/gb/podcast/gut-podcast/id330976727).

When the first human genome was sequenced, the whole project was estimated to have cost some 3 billion dollars and took over 13 years. Now, with massively parallel Next Generation Sequencing it is possible to sequence the human genome in less than 24 hours at a cost of under $1,000. With a rapid decline in sequencing costs, both the number of applications and the amount of data produced have boomed, driving a revolution in medicine. However, with the advent of new enabling technologies, what is next? What are the new and exciting technologies in the sequencing space which will be truly disruptive in the future? And what technical innovation is required to bring these technologies to the mainstream user or even the clinic?In this episode of Invent: Life Sciences, we explore the race to innovate in the sequencing arena, what's happened so far, and what's going to happen next.Find out more on this week's episode of Invent: Life Sciences from TTP.This Week's GuestsDr. Geoff Smith Geoff is a next generation sequencing pioneer who has built and led many of the teams that invented and developed the entire NGS workflow - from sample prep, to the core sequencing technology, to new instrument systems. Previously Ilumina's global head of ​​technology development, he is now an independent board member of various exciting start ups.https://www.linkedin.com/in/geoff-smith-328b5b9/Dr. Lauren LaingLauren leads the 'Omics Team at TTP – a team addressing current needs in DNA and RNA sequencing and also looking to develop tools for future multi- proteo- and other ‘omic workflows. Prior to this Lauren has worked in developing new sequencing technologies, novel chemistries, approaches to automating sample preparation, and research applying sequencing in single cell and epigenetic applications.https://www.linkedin.com/in/epigenomicslvl/  Dr. James HadfieldJames is the Senior Director of Oncology Translational Medicine at AstraZeneca and author of the CoreGenomics blog, enseqlopedia. A life-sciences researcher and senior operational manager with over 20 years' experience in Genomics technologies, James is a thought leader in genomics with a broad network across academia and industry.http://enseqlopedia.com/coregenomicsThe Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.Find out more about our work here: https://www.ttp.com/

Dr Rick Wilson and Dr Elaine Mardis visit the studio as we consider the basics of genomic medicine. Learn how DNA is sequenced, explored and used to inform the diagnosis, prognosis and management of human disease. We hope you can join us!

In this podcast, our Medical Director, Brad Lewis, talks with Jamey Kain, Vice President of Genetic Innovation here at Machaon. Brad and Jamey discuss how we design our genetic panels, what goes in, what stays out and how we think about clinical utility and turnaround time considerations.Don't forget, Machaon offers genetic testing STAT results in 48 hours!

Myriad  Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.References for this episode:Open Access: Addressing Reproductive Healthcare Disparities through Equitable Carrier Screening: Medical Racism and Genetic Discrimination in United States' History Highlights the Needs for Change in Obstetrical Genetics Care https://www.mdpi.com/2075-4698/12/2/33ACMG poster. eP336: A tale of two HBs: DNA Sequencing and hemoglobin electrophoresis. https://www.gimjournal.org/article/S1098-3600(22)00388-4/fulltextThe Evolving Role of Next-Generation Sequencing in Screening and Diagnosis of Hemoglobinopathies. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353275/

Dr. Evan Noch interviews Dr. Mary Jane Lim-Fat about her and her team's recent manuscript entitled: "Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making", published online in Neuro-Oncology in December 2021.

Welcome to Season 3 of the Personalized Medicine Podcast! We hope you all head a good start in 2022 and are ready to dive deep into the world of personalized medicine with us again.In this first episode of Season 3, we address a very important and, frankly speaking, underappreciated topic of sepsis, commonly known as bacterial blood poisoning. Did you know that last year, sepsis killed more people than 5 most common types of cancer combined? For this episode, our host Oleksandr Yagensky sat down with the co-founder and CEO of Noscendo, Dr. Philip Stevens. Philip and his team are developing diagnostic workflows based on detection of bacterial and fungal cell-free DNA from blood to detect infections.Listen to this episode to learn more about: ◦ The founding story of Noscendo ◦ Building a successful diagnostics startup in Europe ◦ Generation of clinical evidence for early stage startups ◦ Misconceptions about sepsis and sepsis diagnostics ◦ How NGS can help detect sepsis early ◦ Role of DNA sequencing in determining antibiotic resistance ◦ Philip's advice to aspiring life science entrepreneursGet in touch with Philip: ◦ LinkedIn: https://www.linkedin.com/in/philip-stevens-4ab68213b/ ◦ Twitter: https://twitter.com/noscendo ◦ Web: https://noscendo.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

FirstWord Pharma PLUS editor Simon King discusses the approval of Bristol Myers Squibb and bluebird bio's CAR-T therapy Abecma for multiple myeloma with senior Therapy Trends analyst Sarah Harris, speaks to Novartis' European gene therapy chief Mike Fraser about the launch of Zolgensma and asks FirstWord HealthTech's Tina Tan why the US Federal Trade Commission is looking to block Illumina's proposed acquisition of Grail in the cancer diagnostics market.